BH3-only proteins in cell death initiation, malignant disease and anticancer therapy
| Autor: | Stephan Kiessling, Verena Labi, Andreas Villunger, Miriam Erlacher |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Programmed cell death
Cell Death biology Bcl-2 family Intrinsic apoptosis Cell Biology Small molecule Cell biology law.invention Cell Transformation Neoplastic Proto-Oncogene Proteins c-bcl-2 Apoptosis law Neoplasms biology.protein Recombinant DNA Animals Humans Tumor Suppressor Protein p53 biological phenomena cell phenomena and immunity Antibody Receptor Molecular Biology |
| Zdroj: | Cell Death & Differentiation. 13:1325-1338 |
| ISSN: | 1476-5403 1350-9047 |
| DOI: | 10.1038/sj.cdd.4401940 |
| Popis: | Induction of apoptosis in tumour cells, either by direct activation of the death receptor pathway using agonistic antibodies or recombinant ligands, or direct triggering of the Bcl-2-regulated intrinsic apoptosis pathway by small molecule drugs, carries high hopes to overcome the shortcomings of current anticancer therapies. The latter therapy concept builds on a more detailed understanding of how Bcl-2-like molecules maintain mitochondrial integrity and how BH3-only proteins and Bax/Bak-like molecules can undermine it. Means to unleash the apoptotic potential of BH3-only proteins in tumour cells, or bypass the need for BH3-only proteins by blocking possible interactions of Bcl-2-like prosurvival molecules with Bax and/or Bak allowing their direct activation, constitute interesting options for the design of novel anticancer therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|